Foundations of Drug Action & Development

Foundational principles of drug action, drug naming, ADME kinetics, pharmacodynamics, dose-response relationships, and drug interaction mechanics.

Learn

Clinical pharmacology starts with mastering how medications are synthesized, classified, named, and introduced into clinical practice. Drugs carry three distinct designations: the precise chemical structure, an official generic nonproprietary identifier, and manufacturer-copyrighted brand names. To minimize medical errors, reliance on generic nomenclature is universally encouraged.

Key Clinical Concepts & Topics

Nomenclature: Chemical, generic, and trade/brand names

Chemical name: Scientific name precisely describing atomic and molecular structure
Generic name: Nonproprietary official identifier listed in pharmacopeias to avoid brand confusion
Trade/brand name: Proprietary designation copyrighted and registered by the manufacturer
The World Health Organization assigns each International Nonproprietary Name as public property so one active substance has a unique identifier. Related drugs often share an INN stem that signals a pharmacologic family. WHO advises that trademarks should not be derived from INNs or contain those stems, because that can confuse patients and block later names in the same family.

Drug classifications: Pharmacologic vs. therapeutic classes

Pharmacologic class: Groups agents by shared biochemical action or mechanism (e.g., beta-adrenergic blockers)
Therapeutic class: Groups agents by intended clinical indication (e.g., antihypertensives)

Drug origins: Natural and synthetic/recombinant sources

Natural derivatives: Plant alkaloids, glycosides, gums, resins, animal hormones, and minerals
Synthetic & Recombinant: Genetically altered bacterial production (e.g., human insulin) and synthetic analogs free from natural impurities
Recombinant DNA technology inserts a human gene into a microorganism such as a bacterium or yeast so the cell produces a therapeutic protein. The U.S. FDA approved Humulin, biosynthetic human insulin made this way, in 1982—the first approved medical product from recombinant DNA. That method reduced reliance on animal pancreatic extracts.

FDA approval pathway: IND application and clinical trial phases I–IV

IND Application: Review of animal toxicity and pharmacology prior to human evaluation
Phase I: Primary assessment of safety, metabolism, and dosing limits in healthy volunteers
Phase II: Initial evaluation of clinical efficacy and safety in targeted diseased subjects
Phase III: Multicenter clinical evaluations with large patient cohorts to uncover rare adverse effects
Phase IV: Post-marketing surveillance to track post-release outcomes and potential toxicities
An IND is filed before human trials begin. It includes animal toxicity data, manufacturing information, and clinical protocols. FDA has 30 days to review the original IND and may allow the study to proceed or place a clinical hold if volunteers would face unreasonable risk.

Administration routes: Enteral, parenteral, topical, and specialized infusions

Enteral: Oral, sublingual, buccal, and rectal options bypassing or utilizing GI absorption
Parenteral: Intravenous, intramuscular, and subcutaneous injections modulating systemic absorption speed
Topical & Specialized: Epidural, intrathecal, intra-articular, intraosseous, and inhalation routes

Read full notes

These notes add mechanisms and relationships. Read one topic at a time.

The four clinical phases

Before therapeutic release, an Investigational New Drug (IND) must undergo four defined clinical phases. Testing transitions sequentially from a small cohort of healthy volunteers in Phase I, to diseased patient trials in Phase II, expanding to large multicenter trials in Phase III, and concluding with post-marketing Phase IV surveillance to identify rare, delayed toxicities.

Chemical, generic, and brand names

A chemical name follows scientific naming of atoms and bonds. It is precise but usually too long for prescribing. The generic name is an International Nonproprietary Name (INN). The World Health Organization places INNs in the public domain for use in pharmacopoeias, labels, regulation, and scientific literature. Related drugs often share an INN stem so clinicians can recognise a pharmacologic family. National names such as United States Adopted Names are usually the same as the INN, with rare exceptions. A trade (brand) name is a manufacturer trademark used for marketing. It can differ by country and is not the official identifier of the substance. WHO advises that trademarks should not be derived from INNs or contain INN stems.

Pharmacologic and therapeutic classes

The same medicine can sit in more than one grouping. A pharmacologic class groups agents that share a biochemical action or mechanism, for example beta-adrenergic blockers. The U.S. Food and Drug Administration defines that class from any combination of mechanism of action, physiologic effect, and chemical structure. A therapeutic class groups agents by the disease or symptom treated, for example antihypertensives. That therapeutic grouping also includes drugs with different mechanisms, such as diuretics. Knowing both helps you predict shared adverse effects from the mechanism and choose among options for the same indication.

Where medicines come from

Medicines come from natural materials, chemical synthesis, or living production systems. Natural sources include plant alkaloids, glycosides, gums, resins, animal hormones, and minerals. Many modern products are chemically synthesised small molecules. Biological products are generally derived from living material—human, animal, or microorganism—and are often complex proteins. Recombinant DNA technology inserts a human gene into a microorganism such as a bacterium or yeast so the cell produces a therapeutic protein. In 1982 the U.S. FDA approved Humulin, biosynthetic human insulin made this way, the first approved medical product from recombinant DNA. That method reduced reliance on animal pancreatic extracts.

IND review and what each phase asks

Before a new drug is given to people in the United States, the sponsor files an Investigational New Drug application. The IND includes animal toxicity data, manufacturing information, and clinical protocols. FDA has 30 days to review the original IND and may allow the study to proceed or place a clinical hold if volunteers would face unreasonable risk. FDA describes typical Phase 1 studies as safety and dosage over several months in about 20 to 100 healthy volunteers or people with the disease; for many cancer drugs, Phase 1 is done in patients with that cancer. About 70% of drugs move on. Phase 2 studies efficacy and side effects in up to several hundred people who have the condition. Phase 3 studies, sometimes called pivotal, test efficacy and monitor adverse reactions in about 300 to 3,000 people over 1 to 4 years. Phase 4 studies continue after approval, because it is impossible to have complete safety information at the time of approval. A common misconception is that Phase 1 always uses only young healthy volunteers; FDA’s description includes people with the disease, and disease-related organ injury can remain hidden until later phases.

Route, first-pass, and bioavailability

The route of administration changes how much drug reaches the bloodstream. Bioavailability (F) is the fraction of an administered dose that reaches the systemic circulation unchanged. An intravenous dose is taken as F = 1 (100%). Oral drugs are usually absorbed in the small intestine, then pass through the gut wall and liver via the portal vein before arterial blood; that presystemic first-pass metabolism can inactivate a large fraction of the dose. Sublingual and buccal doses diffuse into oral venous blood that reaches the superior vena cava and thereby bypass the hepatic portal vein. Rectal absorption only partly avoids first-pass loss. Parenteral injections (intravenous, intramuscular, subcutaneous) also avoid gut first-pass; subcutaneous tissue has fewer vessels, so absorption is slower. Inhaled drugs that reach the pulmonary veins enter the systemic circulation without a hepatic first-pass. Nitroglycerin is a teaching example: oral dosing meets extensive hepatic clearance, whereas sublingual dosing is used when a rapid effect is needed.

Explore

Core Concepts Defined

Chemical Name: The exact scientific description of a compound's atomic structure and chemical bonds.
Generic Name (INN): The standardized, nonproprietary name given to a pharmaceutical substance that remains identical worldwide. The World Health Organization places each International Nonproprietary Name in the public domain so one active substance can be identified across countries; national names are usually the same, with rare exceptions.
Trade / Brand Name: The commercial trademark owned by a specific manufacturer. A brand name can differ by country and is used for marketing; it is not the official identifier of the active substance.
Pharmacologic Class: The grouping of drugs based on their specific biochemical target, molecular mechanism, or receptor family. The U.S. Food and Drug Administration defines pharmacologic class from any combination of mechanism of action, physiologic effect, and chemical structure.
Therapeutic Class: The clinical grouping of medications based on the disease, symptom, or disorder they treat.
Recombinant DNA Technology: A laboratory method that modifies the genetic code of microorganisms (such as bacteria or yeast) to produce complex human therapeutic proteins.
Investigational New Drug (IND): The formal regulatory application submitted to health authorities to seek authorization for testing an experimental molecule in human trials.
Post-Marketing Surveillance (Phase IV): The real-world tracking of safety profiles, adverse events, and therapeutic outcomes in broad patient populations after regulatory clearance.
Bioavailability (F): The fraction or percentage of an administered drug dose that reaches the systemic circulation unchanged. An intravenous dose is taken as F = 1 (100%); other routes are compared with that reference.
First-Pass Effect: The pre-systemic metabolism of an orally swallowed medication within the intestinal mucosa and liver before reaching general arterial circulation. That loss reduces oral bioavailability compared with an intravenous dose of the same drug.

Go deeper: clinical case study

Clinical Case Study 1.1: Drug Safety & Development Breakdown

A pharmaceutical sponsor develops 'Cardiozam-B', a synthetic small-molecule antagonist for hypertension. In Phase I trials with 50 healthy 20-30 year old male volunteers, it produced smooth blood pressure reduction without side effects. However, in Phase II trials with 250 older hypertensive patients with diabetic nephropathy, 12% developed acute renal impairment and hyperkalemia within 72 hours.

Mechanistic Breakdown & Clinical Analysis

Phase I Status: Healthy volunteers have intact nephron reserve and normal potassium clearance, masking renal toxicity.
Phase II Reality: Patients with diabetic nephropathy have baseline microvascular disease. Cardiozam-B altered renal hemodynamics, causing acute kidney injury.
Clinical Takeaway: Phase II is the vital phase where human disease pathology directly interacts with drug pharmacodynamics.

Mastery Question Gate

Answer all questions correctly to unlock the next lesson. Retakes vary the selection when enough questions are available; some questions may repeat.

1. During which clinical evaluation phase is an investigational drug first administered to healthy human volunteers to evaluate pharmacokinetics and safety?

Phase IIPhase IPhase III

2. Why is the generic name considered the safest identifier to use when prescribing and administering medications?

It precisely spells out the molecular and atomic structural arrangement of the compound.It provides a single, universally standardized nonproprietary official name regardless of how many brand names exist.It designates the proprietary trademark restricted exclusively to the original developer.